Helius Medical Technologies, Inc. (HSDT) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2025. Helius Medical Technologies, Inc. is a neurotechnology company focused on the development and commercialization of the Portable Neuromodulation Stimulator (PoNS), a non-implantable medical device for treating gait and balance deficits. The company operates as a single reporting segment. As of June 30, 2025, the company had $6.1 million in cash and cash equivalents.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $43,000 | $182,000 | $92,000 | $317,000 |
| Gross Profit (Loss) | ($53,000) | $64,000 | ($125,000) | $76,000 |
| Operating Expenses | $3,269,000 | $3,334,000 | $7,208,000 | $6,762,000 |
| Net Loss | ($9,833,000) | ($1,612,000) | ($13,671,000) | ($4,128,000) |
| Cash Used in Operating Activities (YTD) | ($6,293,000) vs ($5,892,000) | |||
| Working Capital | $5,998,000 (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 76% in Q2 2025 compared to Q2 2024. This was driven by a decrease in U.S. unit volumes following the termination of temporary cash pay pricing and a significant drop in Canadian sales due to a material breach of the Exclusive Distribution Agreement with Health Tech Connex Inc. (HTC), which was terminated in July 2025.
- Derivative Liability Loss: The company recorded a non-cash loss of $6.0 million in Q2 2025 (and $5.9 million YTD) due to the change in fair value of derivative liabilities associated with warrants issued in the June 2025 offering. This was driven by stock price decreases and exercise price reset provisions.
- Financing Activity: In June 2025, the company completed a public offering generating gross proceeds of $9.1 million. Additionally, warrant inducement exercises in January 2025 generated $3.7 million in gross proceeds. These activities significantly increased cash balances from $1.1 million at year-end 2024 to $6.1 million at June 30, 2025.
- Stock Splits: The company executed two reverse stock splits (1-for-15 in May 2025 and 1-for-50 in July 2025) to regain compliance with Nasdaq listing requirements.
Guidance, Outlook, and Risks
- Going Concern: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern within one year. Management expects to continue incurring operating losses and requires additional capital to fund operations beyond the second quarter of 2026.
- Regulatory & Clinical: The company is on track to submit for FDA authorization for the stroke indication in Q3 2025, with a goal of approval by end of 2025 or early 2026. Preliminary analysis of pivotal stroke studies met primary endpoints.
- Reimbursement: The company secured its first three major commercial payer reimbursements (Anthem, United Healthcare, Aetna) in 2025. However, broad coverage is expected to take at least 24 months to achieve.
- Nasdaq Compliance: The company regained compliance with Nasdaq minimum bid price and stockholders' equity requirements following the reverse stock splits and the June 2025 offering. It is subject to a Mandatory Panel Monitor until July 2026.
- Risks: Key risks include the inability to raise additional capital, potential delisting if compliance is not maintained, and the uncertainty of achieving profitable operations.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $6.1 million cash balance against the burn rate of ~$6.3 million per six months to confirm the timeline for needing new capital.
- Derivative Liability Impact: Confirm the non-cash nature of the $6.0 million loss and its impact on net loss versus actual cash burn.
- Canadian Distribution: Assess the impact of the terminated agreement with Health Tech Connex Inc. on future Canadian revenue streams.
- Reimbursement Progress: Monitor the expansion of commercial payer coverage beyond the initial three approvals to validate the path to profitability.
- Stroke FDA Submission: Track the Q3 2025 submission timeline for the stroke indication as a critical catalyst for future valuation.